QR Code

Towards a new combination therapy for tuberculosis with next generation benzothiazinones

Abstract The benzothiazinone lead compound, BTZ043, kills Mycobacterium tuberculosis by inhibiting the essential flavo‐enzyme DprE1, decaprenylphosphoryl‐beta‐D‐ribose 2‐epimerase. Here, we synthesized a new series of piperazine‐containing benzothiazinones (PBTZ) and show that, like BTZ043, the prec...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Vadim Makarov, Benoit Lechartier, Ming Zhang, João Neres, Astrid M van der Sar, Susanne A Raadsen, Ruben C Hartkoorn, Olga B Ryabova, Anthony Vocat, Laurent A Decosterd, Nicolas Widmer, Thierry Buclin, Wilbert Bitter, Koen Andries, Florence Pojer, Paul J Dyson, Stewart T Cole
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Springer Nature 2014-02-01
Rangatū:EMBO Molecular Medicine
Ngā marau:
benzothiazinones
combination regimens
DprE1
tuberculosis
Urunga tuihono:https://doi.org/10.1002/emmm.201303575
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite